FDA Safety Review of Abortion Pill Mifepristone Extended to 2027
The Food and Drug Administration (FDA) has informed a federal appeals court in New Orleans that its safety review of the abortion pill mifepristone will extend into next year, with a final decision on potential restrictions expected after March 2027.…
Detroit, MI, October 7, 2026 — The U.S. Food and Drug Administration (FDA) has notified a federal appeals court that its comprehensive safety review concerning the abortion pill mifepristone will continue into the following year.
A final determination regarding any potential restrictions on the medication is now anticipated to be issued after March 2027. This timeline update comes amidst ongoing legal challenges that question the accessibility of mifepristone, with particular attention on its distribution via mail.
The legal proceedings involve appeals related to previous court rulings concerning the drug’s status. The FDA’s commitment to a prolonged safety review indicates a detailed examination process is underway. Information about specific aspects of the review or the exact nature of potential restrictions has not been detailed in the court notification.
The agency’s current stance provides a clearer, albeit extended, timeframe for stakeholders involved in the legal and regulatory landscape surrounding mifepristone. The process is unfolding in the federal appeals court located in New Orleans.
Further details regarding the FDA’s safety assessment and the eventual decision on potential restrictions are expected to be disclosed as the review progresses towards its conclusion, scheduled for after March 2027. The contractor’s name was not provided. The fine amount was not provided. The specific violations were not provided.
Story summarized from the original created by Matthew Perrone, Associated Press on www.clickondetroit.com, see more information here.
Media gallery
